News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Merck & Co., Inc.'s Stromectol Wipes Out Hard-to-Treat Lice, Study Finds
March 11, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Merck & Co.’s Stromectol tablet worked better than lotion at clearing up hard-to-treat head lice, a study found, as the infestations become increasingly resistant to current medicines.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Merck & Co.
MORE ON THIS TOPIC
Podcast
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
April 1, 2026
·
1 min read
·
Heather McKenzie
Insights
The Brave New World of Radiotherapeutics
April 1, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Rare diseases
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease
March 31, 2026
·
2 min read
·
Heather McKenzie
Immunology and inflammation
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases
March 31, 2026
·
4 min read
·
Tristan Manalac